stockrow
Friday 6 November 2026
Export HIMS’s income statement to Excel — free account
Hims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
25.43
1.37
+5.69%
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) Total debt
Hims & Hers Health, Inc.'s total debt at the end of fiscal 2025 was $972.6M, up 26,553.3% from $3.6M in fiscal 2022. At the end of the quarter to 30 June 2026 it was $1.4B. Hims & Hers Health, Inc. ranks 11th of 84 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $972.6M | 26,553.33% |
| FY2022 | $3.6M | (11.37%) |
| FY2021 | $4.1M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.4B | 40.16% |
| Mar 2026 | $974.1M | 0.16% |
| Dec 2025 | $972.6M | 0.16% |
| Sep 2025 | $971.0M | 0.16% |
| 10 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| ALKS Alkermes plc compare | $1.5B |
| HIMS Hims & Hers Health, Inc. | $1.4B |
| RDY Dr. Reddy's Laboratories Ltd compare | $753.0M |
| LNTH Lantheus Holdings, Inc. compare | $571.7M |
| SUPN Indivior Pharmaceuticals Inc. compare | $488.0M |
| LQDA Liquidia Corporation compare | $176.1M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $13.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $1.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement